Philip W Kantoff

20120121618, May 17, 2012

Feb 12, 2010

13/201426

Philip W. Kantoff - Brookline MA, US
William K. Oh - Pleasantville NY, US
June M. Chan - Oakland CA, US
Wanling Xie - Newton MA, US
Miyako Abe - Brookline MA, US
Lorelei A. Mucci - Newton MA, US

C12Q 1/68
G01N 33/53
A61K 31/573
A61K 45/00
A61K 38/44
B65D 71/00
A61P 39/06
A61P 37/04
H01J 49/26
B01J 19/12
G06Q 50/24
B65D 85/00
C40B 30/10
A61P 35/00

4241841, 506 12, 435 611, 436501, 514179, 424 944, 250282, 2504921, 705 3, 2064595, 206232

The disclosure features methods and compositions for determining whether a male subject has, or is at an increased risk of developing, an aggressive form of prostate cancer. The disclosure also features methods for adjusting a treatment regimen (e.g., discontinuing a therapy comprising an antioxidant) or administering a therapy that does not contain an antioxidant for a male subject in view of one or both of an MnSOD2 genotype status and an elevated level of an antioxidant in a biological sample obtained from the male subject. Also featured are methods for reducing superoxide levels in a subject based on one or both of an MnSOD2 genotype status and an elevated level of an antioxidant in a biological sample obtained from the male subject.

20120295807, Nov 22, 2012

May 18, 2012

13/475432

Jonathan E. Rosenberg - New York NY, US
Joaquim Bellmunt - Barcelona, ES
Philip Kantoff - Brookline MA, US
Massimo Loda - Belmont MA, US

Dana-Farber Cancer Institute, Inc. - Boston MA

C12Q 1/68
C40B 30/04
G01N 21/64

506 9, 435 614, 435 611

Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.

20130095481, Apr 18, 2013

Feb 11, 2011

13/574001

Philip W. Kantoff - Needham MA, US
Ming Yang - Boston MA, US
Tong Sun - Boston MA, US
Wanling Xie - Chestnut Hill MA, US

DANA-FARBER CANCER INSTITUTE, INC. - Boston MA

C12Q 1/68

435 611

The disclosure provides materials and methods related to using biomarkers for prediction of duration of response to prostate cancer treatment and for treating prostate cancer.

63000601, Oct 9, 2001

May 16, 1996

8/649069

Philip W. Kantoff - Needham MA
Myles Brown - Newton MA
Edward Giovannucci - Wakefield MA

Dana-Farber Cancer Institute, Inc. - Boston MA
The Brigham and Women's Hospital, Inc. - Boston MA

C12Q 168
C12P 1934
C07H 2102
C07H 2104

435 6

There is described a method for prognosis of prostate cancer in a male comprising: (a) determining the length of the CAG trinucleotide repeat of exon 1 of the androgenic receptor gene and/or the length of the TA dinucleotide repeat of the 5 alpha reductase Type II gene or its complement obtained from DNA of the male and (b) correlating the length of the repeat with the aggressiveness and mortality risk of the cancer in the male.

20190024185, Jan 24, 2019

Dec 30, 2016

16/066876

- BOSTON MA, US
PHILIP KANTOFF - NEW YORK NY, US
KAZUMASA KOMURA - NEW YORK NY, US

C12Q 1/6886
A61P 35/00
C12Q 1/6806
C12Q 1/686
A61K 31/337
A61K 31/4166

The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.

20180135132, May 17, 2018

Oct 24, 2017

15/791901

- Boston MA, US
Joaquim Bellmunt - Barcelona, ES
Philip Kantoff - Brookline MA, US
Massimo Loda - Belmont MA, US

Dana-Farber Cancer Institute, Inc. - Boston MA

C12Q 1/6886
C12Q 1/6851

Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.

20170081724, Mar 23, 2017

Mar 17, 2015

15/126423

- Boston MA, US
- New York NY, US
Levi Alexander Garraway - Newton MA, US
Philip Wayne Kantoff - Brookline MA, US
Nikhil Wagle - Boston MA, US

C12Q 1/68
A61K 33/24

A method of increasing the efficacy of treatment for a patient suffering from urothelial carcinoma. The method comprises the steps of determining the presence or absence in a biological sample from the patient of somatic ERCC2 mutation followed by performing appropriate treatment. The absence of somatic ERCC2 mutation indicates that the urothelial carcinoma is likely to be unresponsive to cisplatin chemotherapy, and the patient then undergoes surgery to remove the carcinoma without accompanying cisplatin chemotherapy. The presence of somatic ERCC2 mutation indicates that the uroethelial carcinoma is likely to be responsive to cisplatin chemotherapy and the patient then undergoes surgery to remove the carcinoma accompanied by cisplatin chemotherapy.